Shopping Cart
- Remove All
- Your shopping cart is currently empty
Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation and exhibiting antitumour activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $290 | In Stock | |
5 mg | $755 | In Stock | |
10 mg | $1,200 | In Stock |
Description | Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation and exhibiting antitumour activity. |
In vivo | Methods: Elgemtumab was administered as a single intravenous injection at 20 mg/kg in SCID mice bearing BT474 and BxPC-3 xenografts; in NSG mice bearing BT474 xenografts, it was given every other day at 20 mg/kg for 35 days. Results: Elgemtumab significantly inhibited pHER3 and pAKT levels in both BT474 and BxPC-3 models and slowed tumor growth in the BT474 model. [1] |
Cas No. | 1512559-37-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.